https://doi.org/10.1093/cvr/cvaa123
M
Mária Lódi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
26
Papers
659
Citations
12
h-index
12
i10-index
Mária Lódi is an academic researcher from Ruhr University Bochum. The author has contributed to research in topics: Cardiomyopathy and Myosin Studies & Chemotherapy-induced cardiotoxicity and mitigation & Cardiovascular Function and Risk Factors. The author has an h-index of 12, co-authored 23 publications.
ORCID: 0000-0002-6533-770XPapers by this author
worksEmpagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
2020 · Cardiovascular Research · 307 citations
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies
2023 · Nature Communications · 54 citations
https://doi.org/10.1038/s41467-023-38723-y
Stress activated signalling impaired protein quality control pathways in human hypertrophic cardiomyopathy
2021 · International Journal of Cardiology · 31 citations
https://doi.org/10.1016/j.ijcard.2021.09.009
Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy
2019 · Journal of Translational Medicine · 22 citations
https://doi.org/10.1186/s12967-019-1978-0
Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy
2020 · Journal of Translational Medicine · 14 citations
https://doi.org/10.1186/s12967-020-02564-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat